[A25-78] Amivantamab (NSCLC, first line, combination with lazertinib) - Addendum to Project A25-08
Last updated 17.07.2025
Project no.:
A25-78
Commission:
Commission awarded on 12.06.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations; first-line treatment
- Patients < 65 years: hint of a minor added benefit
- Patients ≥ 65 years: hint of a lesser benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-78
| Project no. | Title | Status |
|---|---|---|
| A25-08 | Amivantamab (NSCLC, first line, combination with lazertinib) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-11 | Lazertinib (NSCLC, first line, in combination with amivantamab) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
17.07.2025 A G-BA decision was published.
G-BA documents on this decision